AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02203253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: 100 mg by mouth twice a day on days 1-5 after chemotherapy, cycle 1
Study NCT02203253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for thalidomide
Description: Placebo tablet manufactured to mimic Thalidomide 25 mg tablet 100 mg by mouth twice a day on days 1-5 after chemotherapy , cycle 1
Study NCT02203253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Palonosetron and Dexamethasone
Description: Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
Study NCT02203253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron and Dexamethasone
Description: Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
Study NCT02584634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg
Study NCT01603368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri
Description: Oil drops with Lactobacillus reuteri DSM 17938, 125 million bacteria=0.2 ml per day
Study NCT01603368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oil drops without Lactobacillus reuteri
Study NCT03788876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrical stimulation
Description: The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre until discharge.
Study NCT03788876 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional care
Description: Physiotherapy protocol will be performed by HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre physiotherapists twice a day, which will consist of exercises for bronchial hygiene, exercises for pulmonary reexpansion, and passive mobilization exercises.
Study NCT03788876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: Physiotherapy protocol will be performed by HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre physiotherapists twice a day, which will consist of exercises for bronchial hygiene, exercises for pulmonary reexpansion, and passive mobilization exercises.
Study NCT02584634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06463922
Description: Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.
Study NCT02584634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.
Study NCT05339191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassionate image workshop
Description: Participants attend a workshop through which they will be supported to develop and use their own compassionate image.
Study NCT03318133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anesthesia
Description: in this study, we plan to make a prospective, multicenter, randomized controlled clinical trial to compare the effects of general anesthesia with endotracheal intubation and ultrasound-guided combined lumbar plexus and sacral plexus block with sedative anesthesia on the prognosis of elderly patients with hip fracture to clarify the clinical value of combined lumbar plexus and sacral plexus block with sedative anesthesia in elderly patients with hip fracture.
Study NCT04587245 — intervention group
Intervention type: OTHER
Intervention: Online questionnaire and interviews
Description: Online questionnaire, financial statements (one month per quarter in 2020) submitted electronically, interview with professional accounting firm and review of data and exit Interview
Study NCT03794245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Men-Centered HIV Testing
Description: The intervention involves bringing mobile HIV testing to venues where men congregate, talking to them as a group about HIV testing, and then providing testing at that venue.
Study NCT03794245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linkage to Care for HIV+ Men
Description: Men diagnosed with HIV are accompanied to the clinic and registered there with the help of a community health worker.
Study NCT03794245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic-based HIV Testing
Description: Individuals present to a clinic and request HIV counseling and testing
Study NCT01674361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bitopertin
Description: Bitopertin once daily orally.
Study NCT03794245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Referral for HIV+ Men
Description: Individuals diagnosed with HIV are referred to the nearest clinic for treatment of HIV
Study NCT03900234 — intervention group
Intervention type: OTHER
Intervention: No intervention will be administered
Description: No intervention will be studied. Clinical and ultrasound examinations will be used to find the prevalence of CVD.
Study NCT00659815 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.
Description: Daily care for contact lenses.
Study NCT00659815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.
Description: Daily care for contact lenses
Study NCT01674361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to bitopertin once daily orally.
Study NCT03271931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active choice
Description: EHR alert prompting cardiologists to make an active choice to prescribe a statin or not.
Study NCT01674361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to bitopertin once daily orally.
Study NCT02227615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mango polyphenolics
Description: Frozen Mango (Keitt) packs provided to subjects.
Study NCT02227615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugary beverage
Description: 15.7g sugar, 3.8g pectin and 0.05g citric acid was added in 100ml of the control beverage.
Study NCT02231957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational text message reminders
Study NCT02231957 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional text message reminders
Study NCT02895841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMART app wearable
Description: Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths').
Study NCT01939106 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: One Piece Drainable Pouch
Study NCT03271931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive choice
Description: EHR passive alert to cardiologists about prescribing a statin
Study NCT03551145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acellular collagen matrix
Description: 3D collagen matrix consists of the collagen porcine type I and III
Study NCT03551145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous free gingival graft
Description: Autogenous graft harvested from the posterior palate
Study NCT00161304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Enanthate
Description: Testosterone Enanthate
Study NCT00161304 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04809727 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical biopsy
Description: 4 quadrant biopsy
Study NCT01674361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
Study NCT02146807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosecond Laser system
Description: Picosecond Laser System for the Treatment of Unwanted Tattoos
Study NCT03321552 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous deep vein arterialization
Description: Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
Study NCT03321552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LimFlow System
Description: Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
Study NCT01674361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SSRI
Description: Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
Study NCT01504542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS110 vaccine
Description: 0.5ml to be administered twice weekly for 18 weeks (36 doses)
Study NCT01504542 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5ml buffered saline placebo to be administered twice weekly for 18 weeks (36 doses)
Study NCT01504542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS110 vaccine
Description: 0.5 mls to be dosed twice weekly for 18 weeks (36 doses)
Study NCT02191995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Study NCT01981122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Study NCT01981122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Enzalutamide is an androgen receptor inhibitor. It is indicated for the treatment of patients with mCRPC who have previously received docetaxel. The enzalutamide dose used in this study will be 160 mg orally once daily.
Study NCT00182663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: Given PO
Study NCT00182663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given PO
Study NCT04333134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3162
Description: Fluzoparib, also known as SHR3162, is an inhibitor of human PARP
Study NCT00182663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO
Study NCT01360164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Description: Participants will be given hUC-MSCs transplantation.
Study NCT02444897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural PCA Ropivacaine
Description: Epidural catheter insertion at T10 level before surgery, the tip of catheter location at T8-9 level.~Total volume: 500ml, 16.7mcg/kg+0.75% Ropivacaine 80ml+N/S
Study NCT02444897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV PCA Fentanyl+nefopam+Ramosetron
Description: Total volume: 84ml, Fentanyl 1000mcg+nefopam 120mg+Ramosetron 0.3mg Basal infusion: 1ml/hr, Bolus: 0.5ml with a lockout time 15min.
Study NCT03124602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red Diamond Disposable Pulse Oximeter Sensor
Description: Noninvasive Pulse Oximeter Sensor
Study NCT02511743 — intervention group
Intervention type: OTHER
Intervention: physicians
Description: physicians taking care of patients with chronic Hepatitis B Virus infection, without intervention
Study NCT00959140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CD3+ T cell depletion
Description: The peripheral blood stem cell product is engineered to deliver a dose of 15 to 20 x10\^7 CD3+ cells/kg recipient body weight. Other components of the graft will not be manipulated and the recipient will receive the total number of cells collected with the exception of minimal losses that occur during the process of CD3+ T cell isolation. Following collection, CD3+ T cells will be enumerated and a portion of the product containing 15 to 20 x10\^7 CD 3+ cells/kg will be set aside. The remainder of the product will be depleted of CD3+ T cells.~Following CD3+ T cell depletion, the CD3+ T cell depleted product will then be combined with the unmanipulated product to provide the specified levels of CD3+ T cells/kg recipient body-weight. The graft is infused into the patient on the same day as selected and within 24 hours of donor aphaeresis.
Study NCT03707184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan
Study NCT03813121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam intravenous infusion
Description: Participants will receive a single drug infusion
Study NCT03813121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo intravenous infusion
Description: Participants will receive a single placebo infusion
Study NCT03813121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine intravenous infusion
Description: Participants will receive a single drug infusion
Study NCT01522274 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise
Description: Brisk walking on a treadmill for 56 minutes 3x per week.
Study NCT01522274 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Videos
Study NCT04348630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated heatwave exposure
Description: Older adults are exposed to a 8-hour simulated exposure
Study NCT01974479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 redirected NK cells
Description: Haploidentical donor NK cells will be expanded and electroporated over 10 days and infused. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day - 7 , and Fludarabine 25 mg/m2/day will be given on day -6 to day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
Study NCT01809561 — intervention group
Intervention type: PROCEDURE
Intervention: tissue biopsy during surgical treatment
Description: The samples collected will test for histological diagnosis of endometriosis and verification tests will be done to characterize the telomeres array and telomerase levels and other characteristics for genomic instability such as spontaneous aneuploidy.
Study NCT00468546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MabThera/Rituxan
Description: 1
Study NCT00468546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 2
Study NCT00468546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 2
Study NCT03707184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV
Study NCT03707184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study NCT00468546 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3
Study NCT01832194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Study NCT05077111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Anesthesia
Description: Group A pre-medicated once using Midazolam 3-4mg intravenous (IV) and Fentanyl 50mcg, placed in the setting position. Using a winged 18G (Gadge), 9cm length Tuohy Epidural needle, a 20G springwound closed tip epidural catheter be inserted between T3-T4. A test dose (5ml) 2% Lidocaine given, followed by 5-8 ml Bupivacaine 0.5% and 50mcg Fentanyl as a loading dose. Further top-up dose of 5 ml Bupivicaine 0.5% after 45 minutes.
Study NCT05077111 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia with One Lung Ventilation
Description: Group B premedicated once by 3-4mg Midazolam IV, Ranitidine 50mg, Metoclopramide 10mg and Dexamethasone 4mg. Preoxygenation with 100% O2. Induction of anesthesia with Propofol (2mg/kg) and Fentanyl (1mcg/kg). Tracheal intubation by 37-39 Fr Double Lumen Endotracheal Tube insertion facilitated with Cisatracurium 0.1mg/kg. and confirmation of its position by Fiberoptic Bronchoscopy. Selective Lung Ventilation strategy can be performed through the endobroncheal tube of the non operated lung once needed. Anesthesia maintained with Isoflurane (1-2%) and Cisatracurium (0.05mg/kg per dose). Later, anesthesia discontinued and extubation after full neuromuscular recovery after reversal of muscle relaxant by Neostigmine (0.05mg/kg) and Atropine (0.02mg/kg).
Study NCT04264845 — intervention group
Intervention type: OTHER
Intervention: Provider Focus
Description: The provider focus groups will be conducted and data from the focus group sessions will be analyzed and used to evaluate clinicians' interpretation of PROs and acceptability of PRO data in routine clinical care. A formal provider training program will be designed and implemented by a subject matter expert. The focus group session will be repeated at 12 months, with the 12month administration having an increased emphasis on barriers, facilitators, and value of PROs in clinical care.
Study NCT00691041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unity in Diversity
Description: HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
Study NCT02121717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar
Description: Take orally
Study NCT00404781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilostazol in addition to aspirin and clopidogrel
Study NCT00404781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol in addition to aspirin and clopidogrel
Study NCT00085540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depsipeptide
Description: Given IV
Study NCT06058494 — intervention group
Intervention type: PROCEDURE
Intervention: Anterior Cruciate Ligament Reconstruction
Description: Reconstruction of the anterior cruciate ligament by means of the three reported techniques, namely single-bundle, single-bundle with extraarticular tenodesis and anatomic double-bundle.
Study NCT00273858 — intervention group
Intervention type: OTHER
Intervention: There is no Intervention. The study is observational.
Description: The study is observational and the prescription follows the SmPC of etanercept.
Study NCT02285764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: Modified carbohydrate
Study NCT02285764 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: As determined by the study site
Study NCT02733692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Understanding Reproductive Health for Ladeez (GURHL) Code
Description: Understanding Reproductive Health for Ladeez (GURHL) Code is an acceptability study to test a web-based application designed with and for young women of color 18 to 25 years old.
Study NCT00585299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Description: 20% calorie from fat diet followed for 8 weeks then maintenance diet for additional 8 weeks
Study NCT00585299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional diet
Description: Traditional low-fat diet with dietitian follow-up in 16 weeks
Study NCT04264845 — intervention group
Intervention type: OTHER
Intervention: Patient Interview
Description: A trained professional interviewer will conduct a one-time, one-hour, semi-structured telephone interview of each subject to better understand patient experiences with HF, the treatment process and quality of life determinants. Two semistructured interviews will be conducted with the first 30 patients who have had LVAD therapy (of the 100 patients who agreed to be interviewed), before and 12 months after device implantation. The goal of these interviews will be to describe patient experiences with LVAD therapy, examine factors influencing quality of life, and determine whether currently available PRO tools are likely to capture the intended experiences in HF as they relate to LVAD therapy.
Study NCT00585299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional diet
Description: Traditional low-fat diet with dietitian follow-up in 16 weeks